News & Press Release

February 2012 President Shiomura spoke at the symposium of the 7th International Conference of Rare Disease(ICORD). PDF (428 KB)
January 2012 Sales start for Foscavir® by own sales force
January 2012 Training session for all employees held in Atami, two days, one night
January 2012 Establishment of Tokyo Distribution Center
January 2012 January 2012　Launch Fostoin®750ｍｇ for Injection PDF(208 KB)
January 2012 MA transfer of Foscavir® from AstraZeneca Japan under license agreement with Clinigen
January 2012 Announcement of Organizational Changes and Personnel AssignmentsPDF(43.3 KB)
December 2011 Announcement of Personnel Assignments PDF(46.3 KB)
November 2011 NHI Drug Price listing of Fostoin® 750mg for Injection (NPC-06 Fosphenytoin)
November 2011 NPC-10 Streptozocin designated as an orphan drug.
November 2011 Submitted application for approval of Manufacturing and Marketing Authorization of NPC-08 Gliadel® Wafer (Carmustine).
November 2011 President Shiomura gave a press conference at the Foreign Correspondent’s Club of Japan. PDF(75 KB)
November 2011 President Shiomura spoke at the Japan Society of Pediatric Clinical Pharmacology and Therapeutics Symposium.
November 2011 Announcement of Personnel Assignments PDF(46.4 KB)
October 2011 President Shiomura spoke at the Japan Health Sciences Foundation.
September 2011 License Agreement with Clinigen for FoscavirR (Antivirus medicine) sales right
August 2011 As a Director of SAMURAI Biotech Association, President Shiomura was appointed as a constituent member of the Study Group for Stimulation of Clinical Research and Trials
August 2011 NPC-11 Caffeine Citrate was designated as the orphan drug.
July 2011 Training session for all employees held in Atami, two days, one night (pic)
July 2011 Announcement of Organizational Changes and Personnel Assignments PDF(33.0 KB)
June 2011 Sendai office opening reception (pic1) (pic2) (pic3) (pic4)　
June 2011 Announcement of Start of Phase III Trial of Drug for Apnea of Prematurity PDF (69.0 KB)
June 2011 Fosphenytoin® Intravenous 750mg recommended approvable by Product Evaluation Office of New Drug I, Pharamaceuticals
and Medical Devices Agency, Japan
May 2011 NPC-11 (caffeine citrate) Clinical Trials Notification submitted
May 2011 Nobelpharma President & CEO Jin Shiomura, a director of SAMURAI Biotech Association, was appointed to be a constituent member for Introduction of the Regulatorial Strategy Consultation services for Pharmaceuticals and Medical Devices.
May 2011 Lunabell® compound tablets recall rehearsal
May 2011 Announced opening of new office (Sendai)
April 2011 NPC-10 (Streptozocin) face-to-face consultation
April 2011 Announced opening of new office (Sapporo)
April 2011 Natural-type Interferon Beta Formulation Feron(R) Joint Information Provision in the Field of Neurosurgery PDF(13.3KB)
April 2011 Marketing organization : 47MRs
March 2011 Support for victims and affected areas of the Great East Japan EarthquakePDF(61.4KB)
March 2011 NPC-11 (caffeine citrate) face-to-face consultation
March 2011 Held the 8th General Shareholders Meeting
January 2011 Training session for all employees held in Atami, two days, one night(pic1)(pic2)(pic3)(pic4)
January 2011 Nobelpharma, the only Japanese company to give a presentation at Bio Asia, held on January 24 and 25
January 2011 New Years prayers at Kanda Shrine and Koami Shrine
December 2010 Notification of organizational changes and personnel assignmentsPDF(48KB)
December 2010 Notification of additional indication for LunabellR compound tabletsPDF(41KB)
November 2010 Moon Voice launched
November 2010 Concluded contract with U.S. company UPI (Emil Kakkis, M.D., Ph.D., President) to conduct joint international research
for clinical drug for distal myopathy
October 2010 Osaka office opening reception(picture1) (picture2)
October 2010 Notification of organizational changes and personnel assignments of 35 marketing personnel and establishment of
8 branch officesPDF(54KB)
October 2010 Marketing organization: added 15 MR personnel
September 2010 NPC-07 (5-aminolevulinic acid) designated as orphan drug
September 2010 Fukuoka office opening reception(picture1)(picture2)
September 2010 Local: participated in Kobunacho Community festival(picture1)(picture2)
September 2010 Participated as symposist Japanese Society of Social Pharmacy's “Social Pharmacy, Contributing to the Quality
and Safety of Medicine”
August 2010 Personnel assignments announced
August 2010 Held Tokyo Office Opening Reception party
August 2010 Tokyo Municipal Office conducted first-hand inspection on renewal of business license to produce and sell pharmaceuticals
July 2010 Submitted notice of ending IND of NPC-05
July 2010 Held Nagoya Office Opening Reception party
July 2010 All employees participate in two-day overnight study tour
June 2010 Personnel assignments announced
June 2010 Announced new business facilities
May 2010 Announced start of Phase III clinical trial for oral diagnostic medicine for malignant glioma
May 2010 The Japanese Society of Child Neurology announces “Status Epilepticus in Japan”
April 2010 Business organization: 12 Medical Reps entered the company, and there are now 22 Medical Reps
March 2010 Mr. Jin Shiomura, CEO, gave presentation to the 130th Annual Meeting of the Pharmaceutical Society of Japan about on “Issues in obtained from cases and experience in Drug Re-profilingPDF(308KB)
January 2010 Information about organization and personnel changesPDF(17KB)
November 2009 Information about organization and personnel changesPDF(23KB)
September 2009 Information about organization and personnel changesPDF(22KB)
June 2009 NPC-08 GLIADEL® WAFER was registered as Orphan Drug
May 2009 Information about personnel changes PDF(36KB)
April 2009 License Agreement for Japan of GLIADEL® WAFER was concluded PDF(54KB)
March 2009 Information about personnel changes PDF(39KB)
February 2009 JAN (Japanese Accepted Name) of Fosphenytoin Sodium Hydrate is registered
December 2008 Sales start for NPC-03 (Nobelbar® Intravenous Phenobarbital)
NHI price listing for NPC-03 (Nobelbar® Intravenous Phenobarbital)
PDF(38KB)
October 2008 Approval received for manufacturing and sales of NPC-03
(Nobelbar® Intravenous Phenobarbital)
August 2008 Approval of NPC-03 （Nobelbar® Intravenous Phenobarbital）
completed after examination by1st Committee on New Drug
July 28,2008 Announcement of the contract between Alfresa Pharma Corporation and Nobelpharma for development and sales collaboration PDF (62KB)
July 2008 Sales start for Lunabell® compound tablets (IKH-01)
June 2008 NHI price listing for Lunabell® (IKH-01)
April 2008 Sales start for Nobelzin® capsules (NPC-02) NHI price listing for Nobelzin® capsules (NPC-02)
Approval received for manufacturing and sales of Lunabell® compound tablets (IKH-01)
January 2008 NPC-02 (Nobelzin® capsules; zinc acetate preparation) received approval for manufacturing and sales